Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Budapest, Hungary
- Accelsiors CRO and Consultancy Services
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-30 years old
- GHD of childhood onset
- completed growth
- IGF-1 <=2SDS
- rhGH treatment naive
- hGH levels below cut-off
Exclusion Criteria:
- History of malignancy or intracranial tumors
- ECG abnormality
- ICH
- hepatic dysfunction
- renal impairment
- major medical conditions
- inadequate T4
- positive for HBV, HCV, or HIV
- alcohol or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
low dose
|
Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
|
|
Active Comparator: 2
Medium dose
|
Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
|
|
Active Comparator: 3
High Dose
|
Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Temporal profiling of circulating IGF-1 levels.
Time Frame: 3 period
|
3 period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body composition measurements at start of study and end of study
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Mihaly Juhasz, MD, Accelsiors CRO & Consultancy Services
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO-ARX201-701
- EudraCT: 2007-001746-40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.